PVG Counters ISS: Board's 'Failed Oversight' Cited in Push for Gold Card Vote
AVXL is trading near its 52-week low of $2.255 (11% above the low) on light trading volume (0.4× avg).
Summary
PVG Asset Management issued a press release attacking ISS's support for Anavex's incumbent board, citing the proxy advisor's own critical findings on governance failures and urging stockholders to vote the GOLD card for PVG's six nominees.
Key Events · Corporate Governance and Compliance · AVXL
-
PVG Rebuts ISS Recommendation
PVG issued a press release on September 14, 2026, attacking ISS's support for Anavex's incumbent board nominees, arguing the proxy advisor's own report documents years of failed governance and shareholder value destruction.
-
ISS Findings Quoted
PVG highlights ISS's lowest-possible QualityScore of 10 for Audit & Risk Oversight, the board's admission of minimal meetings with officers beyond the former CEO for over 12 years, and only one director owning stock (5,000 shares).
-
Governance Concerns Detailed
ISS noted the same person has chaired the audit, compensation, and nominating committees since 2018, and that the vote standard could act as an entrenchment mechanism.
-
Investor Conference Call Announced
PVG will host an investor conference call on September 16, 2026, at 10:00 a.m. Eastern Time to discuss its campaign for board change.
Analysis · AVXL · Life Sciences
PVG Asset Management is escalating its proxy fight against Anavex's board by publicly rebutting ISS's recommendation to support the incumbent directors. The filing quotes ISS's own findings — a lowest-possible QualityScore of 10 for audit oversight, the board's admission it rarely met with officers beyond the former CEO for over 12 years, and only one director owning a token 5,000 shares — to argue the board has failed shareholders. With the annual meeting set for September 24, this is a direct attempt to sway undecided voters ahead of the showdown.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231.7M. The 52-week trading range was $2.26 to $10.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.